ANKRD29 Inhibitors

ANKRD29 inhibitors are chemicals, some of which are known to indirectly influence proteins with ankyrin repeats by targeting certain pathways they're involved in. One such pathway is the NF-kappaB signaling cascade, a pivotal pathway in cellular inflammation and immunity. Given the ubiquity of ankyrin repeat domains in the NF-kappaB pathway, inhibitors that target this signaling cascade can, in turn, impact proteins containing ankyrin repeats.

Cardamonin, for instance, can disrupt the NF-kappaB pathway, thereby potentially affecting the function of proteins, such as ANKRD29, with ankyrin repeats. IKK (IκB kinase) inhibitors, like Ro 106-9920, Wedelolactone, and BAY 11-7082, can modulate the NF-kappaB signaling by targeting the upstream regulatory kinases, indirectly affecting the ankyrin repeat domain-containing proteins. Another angle of interaction is via molecules such as JSH-23, which blocks the nuclear translocation of NF-kappaB p65, subsequently affecting downstream proteins. Parthenolide, on the other hand, interacts with the IκB kinase complex, playing a role in the modulation of ankyrin-containing proteins. Moreover, inhibitors like IMD-0354, ML120B, sc-514, TPCA-1, BMS-345541, and PS-1145 are known to target various facets of the NF-kappaB pathway, which in turn can influence the functional state of proteins, potentially including ANKRD29, with ankyrin repeats.